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earlier clinical impact item reduction, where Juniper 
et al’s clinical impact method was adapted on a dataset
with a ﬁve-point anchor.
RESULTS: Factor analysis resulted in 24 items. 21 items
with factor loadings above 0.6 were items with high clin-
ical impact scores from the clinical impact approach.
Three items with low to moderate impact scores loaded
high in the factor analysis method. 2 factors, each had
items loading from 3 similar domains, suggesting they
merged into a single factor. This led to 7 factors from an
initial 11-factor solution, similar to the clinical impact
method and with relatively minor differences in items.
CONCLUSIONS: The factor analysis approach to item
reduction produced a PTRQoL instrument with domains
similar to the clinical impact approach. Measurement
properties of the instrument developed using both
methods may decide the optimal approach. Results from
the 2 separate datasets and methods provide evidence for
the robustness of the underlying conceptual framework
of the PTRQoL.
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OBJECTIVE: To investigate one of the most common
misunderstandings on the number needed to treat (NNT)
that implies ‘certainly’, not statistically, one adverse event
can be prevented if the patients of the NNT size are
treated with the new therapy: to correct the wrong inter-
pretation, we developed the odds method for the NNT to
describe the beneﬁt vs. non-beneﬁt of therapy.
METHOD: The binomial distribution, B(n,p), was used
to model and simulate the probabilistic outcomes of
therapy with the NNT and the absolute risk reduction
(ARR) assigned to the trial size n and the event proba-
bility p, respectively. In this model, r out of n patients can
prevent the adverse event with the probability P(x = r)
deﬁned by B(n,p). We calculated the values of the P(x =
r) according to any case for r = 0, 1, 2, . . . , NNT as the
size of NNT increases from one to larger numbers. More-
over, we developed the formula, as a function of NNT, to
represent the odds of beneﬁt vs. non-beneﬁt of therapy,
i.e., P(x ≥ 1)/P(x = 0).
RESULTS: The probabilities of non-beneﬁt, i.e., P(x = 0),
were between .25 and .40 for any size of NNT. It sug-
gested the likelihood of non-beneﬁt of therapy cannot be
negligible even if the NNTs of small size seem to be ‘ben-
eﬁcial’. The numerical evaluation of the odds formula
showed that the larger the sizes of NNT became, the
smaller did the values of the odds. The progression over
the NNTs of more than ﬁve was lower than 2.0, asymp-
totically converging to e-1 (i.e., about 1.7) as the size of
NNT increases to inﬁnity.
CONCLUSIONS: Although the NNT is a quite useful
benchmark of the beneﬁt of therapy, we must interpret 
it as carefully as possible with the odds that indicates 
the ‘relative’ beneﬁt associated with the non-beneﬁt of
therapy.
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Cost minimization analysis (CMA) requires equivalent
comparators. Published guidelines have not adequately
described criteria for assuring equivalence between phar-
macotherapies.
OBJECTIVES: This study aimed to determine the pro-
portion of published CMAs that provided evidence of
equivalence between drug comparators.
METHODS: Medline, Embase, IPA, and Econlit data-
bases were searched using text words “cost” and “mini-
mization”. Inclusion criteria were: original research
claiming to be a CMA that compared costs between
drugs, and were published as full articles (i.e., not
abstracts). Data extracted included: data demonstrating
equivalence, drug class, and journal type. Adequacy of
evidence was assessed by two raters and was based on
source of evidence, quality and strength of effectiveness
data, outcome of interest, and rater’s overall impression.
Veriﬁcation was through consensus.
RESULTS: The search identiﬁed 416 studies; 358 were
rejected (272 did not compare drugs, 63 did not claim 
to be CMAs, 23 were abstracts); 12 were unavailable.
Journals publishing the 46 accepted studies were: general
medical (n = 24), hospital/pharmacy (n = 15), and health
economics (n = 2). Based on adequacy criteria, 7 (15%)
studies were judged “adequate”, 12 (26%) were “ques-
tionable”, and 27 (59%) “failed” to provide adequate
evidence of equivalence. Of those studies judged “ade-
quate”, drugs examined included: antibacterials (n = 4),
cardiovasculars (n-2), and antineoplastics (n = 1). Four of
those seven were published in general medical journals.
CONCLUSION: The majority of studies failed to provide
adequate evidence to justify using CMA as an analytic
technique. Guidelines should be developed that explicitly
specify criteria for CMA, and future authors should
comply with those guidelines. Further study should
examine CMAs not exclusively dealing with drugs and on
studies that are CMAs but do not claim to be.
